Twice vs Thrice Weekly Incident Hemodialysis in Elderly Patients
NCT ID: NCT06141798
Last Updated: 2024-05-31
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
NA
Total Enrollment
428 participants
Study Classification
INTERVENTIONAL
Study Start Date
2021-11-23
Study Completion Date
2026-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
As Korea is becoming a super-aged society, the number of elderly patients with end-stage kidney disease (ESKD) is expected to increase rapidly. Therefore, the burden on Korean society will also increase.
Thrice-weekly hemodialysis is standard for renal replacement therapy. However, this regimen has not been validated for elderly ESKD patients with residual renal function. Elderly patients can have multiple comorbidities such as hypertension, diabetes, cardiovascular disease, and impaired physical activity. Frequent hemodialysis could provoke falls, hypotension, and cognitive impairment. Previous reports have suggested the potential benefit of twice-weekly hemodialysis with incremental increases in frequency when residual renal function decreases. In addition, twice-weekly hemodialysis decreases hospitalization rates in frail patients.
Therefore, the investigators hypothesized initiating renal replacement therapy with twice-weekly hemodialysis decreases the hopsitalizatoin rates compared with conventional thrice-weekly hemodialysis in elderly ESRD patients with residual renal function. This study is a pragmatic randomized clinical trial, multicenter study. Study subjects are incident ESRD patients (\>= 60 years old, n=428) with residual urine volume ( \> 500 mL/day) and follow up up to 2 years. Twice-weekly hemodialysis could be incremented according to clinical situations such as volume overload, hyperkalemia and uremic symptom. Primary outcome of this study is hospitalization rate during follow-up. Secondary outcomes include dialysis related hospitalization rate, the length of hospital stay, complication of dialysis,mortality rate and assessments of quality of life, frailty, and cost-utility.
Thrice-weekly hemodialysis is standard for renal replacement therapy. However, this regimen has not been validated for elderly ESKD patients with residual renal function. Elderly patients can have multiple comorbidities such as hypertension, diabetes, cardiovascular disease, and impaired physical activity. Frequent hemodialysis could provoke falls, hypotension, and cognitive impairment. Previous reports have suggested the potential benefit of twice-weekly hemodialysis with incremental increases in frequency when residual renal function decreases. In addition, twice-weekly hemodialysis decreases hospitalization rates in frail patients.
Therefore, the investigators hypothesized initiating renal replacement therapy with twice-weekly hemodialysis decreases the hopsitalizatoin rates compared with conventional thrice-weekly hemodialysis in elderly ESRD patients with residual renal function. This study is a pragmatic randomized clinical trial, multicenter study. Study subjects are incident ESRD patients (\>= 60 years old, n=428) with residual urine volume ( \> 500 mL/day) and follow up up to 2 years. Twice-weekly hemodialysis could be incremented according to clinical situations such as volume overload, hyperkalemia and uremic symptom. Primary outcome of this study is hospitalization rate during follow-up. Secondary outcomes include dialysis related hospitalization rate, the length of hospital stay, complication of dialysis,mortality rate and assessments of quality of life, frailty, and cost-utility.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Twice Weekly Hemodialysis in Patients With Residual Kidney Function
NCT03874117
Hemodialysis
Kidney Failure, Chronic
COMPLETED
NA
Hemodiafiltration Versus Hemodialysis in Older People
NCT07278973
Hemodialysis
Hemodiafiltration
Fatigue Symptom
+2 more
NOT_YET_RECRUITING
NA
RandomizEd ClinicAL triaL on the Efficacy and saFety of Incremental Hemodialysis (REAL-LIFE)
NCT04360694
End Stage Renal Disease on Dialysis
RECRUITING
NA
Long-term Outcome of End-stage Renal Disease Patients Treated With Hig-efficiency Hemodiafiltration
NCT02576873
End-stage Renal Disease
COMPLETED
Frequent Hemodialysis Network: Daily Trial
NCT00264758
End Stage Renal Disease
COMPLETED
PHASE2/PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
End-stage kidney disease (ESKD) poses a substantial public health challenge, with the number of patients requiring renal replacement therapy (RRT) globally reaching 2.61 million in 2010 and projected to rise to 5.43 million by 2030. In Korea, the incidence of hemodialysis (HD) has also been gradually increasing. The increase in HD incidence in South Korea is significantly linked to the aging population. Korea is one of the most rapidly aging countries in the world and the age of dialysis patients is also increasing, with more than half over the age of 60.
HD has potential advantages over conservative management or peritoneal dialysis in older adults, however, guidelines for optimal HD for the elderly have not yet been established. Typically, patients receive HD three times a week, with only a small proportion of patients receiving less frequent dialysis. However, potential disadvantages such as hemodynamic stress, vascular access problems, bleeding, falls and economic cost should be considered in older adults with ESKD.
In elderly patients, it is often difficult to maintain a thrice-weekly HD schedule due to the presence of other medical conditions and the challenges of frailty. Elderly patients have shown poor outcome even after initiation of HD. A study by Santos et al. demonstrated a more than twofold increased risk of mortality at 6 months in patients older than 75 years compared to those younger than 75. Another study using Japanese National Dialysis Registry data revealed a 30% mortality rate in those aged over 80 years within 1 year after initiation of HD, with frailty being one of the most important factors associated with early death after initiation of HD. Excessive HD in elderly patients can lead to malnutrition, low blood pressure during dialysis, poor quality of life, depression, and stress due to physical and temporal activity restriction. The increased risk of falls in HD patients is also a serious problem.
Incremental initiation of HD involves starting HD at a lower intensity than the standard 4 hours thrice weekly and gradually increasing the frequency and duration of dialysis as kidney function declines. The decision to initiate patients on incremental HD can be made based on clinical parameters such as urine volume or residual kidney function, socio-economic factors such as financial limitations or insurance coverage, or lack of availability of dialysis services. Current guidelines recommend that twice weekly dialysis be performed in patients with kidney urea clearance greater than 3ml/min/1.73m2 or a urine output over 0.5 liter per day.
A systemic review and meta-analysis showed no difference in mortality, hospitalization rates, or quality of life between patients receiving incremental and conventional HD, with improved preservation of residual renal function and a reduction in dialysis cost with incremental HD. One randomized controlled trial (RCT) showed no difference in episodes of fluid overload or hyperkalemia, but an increased risk of hyperkalemia with incremental HD. Another study showed lower hospitalization rate in incremental HD compared to conventional dialysis. These studies demonstrate the need for a large RCT comparing incremental and conventional HD.
However, current studies do not provide conclusive evidence on the benefits and risks of incremental HD in elderly patients. Therefore, the investigators are conducting a pragmatic RCT to determine whether the initiation of renal replacement therapy with twice-weekly HD reduces hospitalization rates compared to conventional thrice-weekly HD in older adults with ESKD.
Trial design PRIDE trial is designed as a pragmatic RCT comparing the effect of initiating twice-weekly hemodialysis with an incremental approach compared to thrice-weekly HD on hospitalization rates in elderly ESKD patients with RKF. A total of 428 participants will be recruited from 18 academic dialysis centers in Korea. Participants will have the flexibility to transfer to other dialysis centers as needed. The decision to increase dialysis frequency will be made by the treating physicians.
Hypothesis Our main hypothesis is that twice-weekly HD, when prescribed to older adults with RKF will reduce hospitalization rates compared with thrice-weekly HD.
1. Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet 2015;385:1975-1982.
2. Hong YA, Ban TH, Kang CY, et al. Trends in epidemiologic characteristics of end-stage renal disease from 2019 Korean Renal Data System (KORDS). Kidney Res Clin Pract 2021;40:52-61.
3. Choi HS, Han KD, Oh TR, et al. Trends in the incidence and prevalence of end-stage renal disease with hemodialysis in entire Korean population: A nationwide population-based study. Medicine (Baltimore) 2021;100:e25293.
4. Verberne WR, Geers AB, Jellema WT, Vincent HH, van Delden JJ, Bos WJ. Comparative Survival among Older Adults with Advanced Kidney Disease Managed Conservatively Versus with Dialysis. Clin J Am Soc Nephrol 2016;11:633-640.
5. Corbett RW, Brown EA. Conventional dialysis in the elderly: How lenient should our guidelines be? Semin Dial 2018;31:607-611.
6. Bieber B, Qian J, Anand S, et al. Two-times weekly hemodialysis in China: frequency, associated patient and treatment characteristics and Quality of Life in the China Dialysis Outcomes and Practice Patterns study. Nephrol Dial Transplant 2014;29:1770-1777.
7. Santos J, Oliveira P, Malheiro J, et al. Predicting 6-Month Mortality in Incident Elderly Dialysis Patients: A Simple Prognostic Score. Kidney Blood Press Res 2020;45:38-50.
8. Yazawa M, Kido R, Ohira S, et al. Early Mortality Was Highly and Strongly Associated with Functional Status in Incident Japanese Hemodialysis Patients: A Cohort Study of the Large National Dialysis Registry. PLoS One 2016;11:e0156951.
9. Buemi M, Lacquaniti A, Bolignano D, et al. Dialysis and the elderly: an underestimated problem. Kidney Blood Press Res 2008;31:330-336.
10. Wang HH, Wu JL, Lee YC, et al. Risk of Serious Falls Between Hemodialysis and Peritoneal Dialysis Patients: A Nationwide Population-based Cohort Study. Sci Rep 2020;10:7799.
11. Caton E, Sharma S, Vilar E, Farrington K. Impact of incremental initiation of haemodialysis on mortality: a systematic review and meta-analysis. Nephrol Dial Transplant 2023;38:435-446.
12. Hemodialysis Adequacy Work G. Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis 2006;48 Suppl 1:S2-90.
13. Kalantar-Zadeh K, Unruh M, Zager PG, et al. Twice-weekly and incremental hemodialysis treatment for initiation of kidney replacement therapy. Am J Kidney Dis 2014;64:181-186.
14. Vilar E, Kaja Kamal RM, Fotheringham J, et al. A multicenter feasibility randomized controlled trial to assess the impact of incremental versus conventional initiation of hemodialysis on residual kidney function. Kidney Int 2022;101:615-625.
15. Murea M, Patel A, Highland BR, et al. Twice-Weekly Hemodialysis With Adjuvant Pharmacotherapy and Transition to Thrice-Weekly Hemodialysis: A Pilot Study. Am J Kidney Dis 2022;80:227-240 e221.
HD has potential advantages over conservative management or peritoneal dialysis in older adults, however, guidelines for optimal HD for the elderly have not yet been established. Typically, patients receive HD three times a week, with only a small proportion of patients receiving less frequent dialysis. However, potential disadvantages such as hemodynamic stress, vascular access problems, bleeding, falls and economic cost should be considered in older adults with ESKD.
In elderly patients, it is often difficult to maintain a thrice-weekly HD schedule due to the presence of other medical conditions and the challenges of frailty. Elderly patients have shown poor outcome even after initiation of HD. A study by Santos et al. demonstrated a more than twofold increased risk of mortality at 6 months in patients older than 75 years compared to those younger than 75. Another study using Japanese National Dialysis Registry data revealed a 30% mortality rate in those aged over 80 years within 1 year after initiation of HD, with frailty being one of the most important factors associated with early death after initiation of HD. Excessive HD in elderly patients can lead to malnutrition, low blood pressure during dialysis, poor quality of life, depression, and stress due to physical and temporal activity restriction. The increased risk of falls in HD patients is also a serious problem.
Incremental initiation of HD involves starting HD at a lower intensity than the standard 4 hours thrice weekly and gradually increasing the frequency and duration of dialysis as kidney function declines. The decision to initiate patients on incremental HD can be made based on clinical parameters such as urine volume or residual kidney function, socio-economic factors such as financial limitations or insurance coverage, or lack of availability of dialysis services. Current guidelines recommend that twice weekly dialysis be performed in patients with kidney urea clearance greater than 3ml/min/1.73m2 or a urine output over 0.5 liter per day.
A systemic review and meta-analysis showed no difference in mortality, hospitalization rates, or quality of life between patients receiving incremental and conventional HD, with improved preservation of residual renal function and a reduction in dialysis cost with incremental HD. One randomized controlled trial (RCT) showed no difference in episodes of fluid overload or hyperkalemia, but an increased risk of hyperkalemia with incremental HD. Another study showed lower hospitalization rate in incremental HD compared to conventional dialysis. These studies demonstrate the need for a large RCT comparing incremental and conventional HD.
However, current studies do not provide conclusive evidence on the benefits and risks of incremental HD in elderly patients. Therefore, the investigators are conducting a pragmatic RCT to determine whether the initiation of renal replacement therapy with twice-weekly HD reduces hospitalization rates compared to conventional thrice-weekly HD in older adults with ESKD.
Trial design PRIDE trial is designed as a pragmatic RCT comparing the effect of initiating twice-weekly hemodialysis with an incremental approach compared to thrice-weekly HD on hospitalization rates in elderly ESKD patients with RKF. A total of 428 participants will be recruited from 18 academic dialysis centers in Korea. Participants will have the flexibility to transfer to other dialysis centers as needed. The decision to increase dialysis frequency will be made by the treating physicians.
Hypothesis Our main hypothesis is that twice-weekly HD, when prescribed to older adults with RKF will reduce hospitalization rates compared with thrice-weekly HD.
1. Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet 2015;385:1975-1982.
2. Hong YA, Ban TH, Kang CY, et al. Trends in epidemiologic characteristics of end-stage renal disease from 2019 Korean Renal Data System (KORDS). Kidney Res Clin Pract 2021;40:52-61.
3. Choi HS, Han KD, Oh TR, et al. Trends in the incidence and prevalence of end-stage renal disease with hemodialysis in entire Korean population: A nationwide population-based study. Medicine (Baltimore) 2021;100:e25293.
4. Verberne WR, Geers AB, Jellema WT, Vincent HH, van Delden JJ, Bos WJ. Comparative Survival among Older Adults with Advanced Kidney Disease Managed Conservatively Versus with Dialysis. Clin J Am Soc Nephrol 2016;11:633-640.
5. Corbett RW, Brown EA. Conventional dialysis in the elderly: How lenient should our guidelines be? Semin Dial 2018;31:607-611.
6. Bieber B, Qian J, Anand S, et al. Two-times weekly hemodialysis in China: frequency, associated patient and treatment characteristics and Quality of Life in the China Dialysis Outcomes and Practice Patterns study. Nephrol Dial Transplant 2014;29:1770-1777.
7. Santos J, Oliveira P, Malheiro J, et al. Predicting 6-Month Mortality in Incident Elderly Dialysis Patients: A Simple Prognostic Score. Kidney Blood Press Res 2020;45:38-50.
8. Yazawa M, Kido R, Ohira S, et al. Early Mortality Was Highly and Strongly Associated with Functional Status in Incident Japanese Hemodialysis Patients: A Cohort Study of the Large National Dialysis Registry. PLoS One 2016;11:e0156951.
9. Buemi M, Lacquaniti A, Bolignano D, et al. Dialysis and the elderly: an underestimated problem. Kidney Blood Press Res 2008;31:330-336.
10. Wang HH, Wu JL, Lee YC, et al. Risk of Serious Falls Between Hemodialysis and Peritoneal Dialysis Patients: A Nationwide Population-based Cohort Study. Sci Rep 2020;10:7799.
11. Caton E, Sharma S, Vilar E, Farrington K. Impact of incremental initiation of haemodialysis on mortality: a systematic review and meta-analysis. Nephrol Dial Transplant 2023;38:435-446.
12. Hemodialysis Adequacy Work G. Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis 2006;48 Suppl 1:S2-90.
13. Kalantar-Zadeh K, Unruh M, Zager PG, et al. Twice-weekly and incremental hemodialysis treatment for initiation of kidney replacement therapy. Am J Kidney Dis 2014;64:181-186.
14. Vilar E, Kaja Kamal RM, Fotheringham J, et al. A multicenter feasibility randomized controlled trial to assess the impact of incremental versus conventional initiation of hemodialysis on residual kidney function. Kidney Int 2022;101:615-625.
15. Murea M, Patel A, Highland BR, et al. Twice-Weekly Hemodialysis With Adjuvant Pharmacotherapy and Transition to Thrice-Weekly Hemodialysis: A Pilot Study. Am J Kidney Dis 2022;80:227-240 e221.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Age Problem
Dialysis; Complications
Frailty
Quality of Life
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Pragmatic Randomization Trial
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Twice-weekly hemodialysis with incremental approach
Group Type
ACTIVE_COMPARATOR
Hemodialysis
Intervention Type
OTHER
Number of weekly hemodialysis treatment
Thrice-weekly hemodialysis
Group Type
NO_INTERVENTION
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hemodialysis
Number of weekly hemodialysis treatment
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥60 years
* Clinical diagnosis of end stage kidney disease
* Starting maintenance hemodialysis within one month
* 24-hour urine output ≥ 500 ml at randomization
* Sufficient understanding of the study procedures and requirements.
* Clinical diagnosis of end stage kidney disease
* Starting maintenance hemodialysis within one month
* 24-hour urine output ≥ 500 ml at randomization
* Sufficient understanding of the study procedures and requirements.
Exclusion Criteria
* Left ventricular ejection fraction \< 40%)
* Liver cirrhosis
* Current treatment for an active malignancy or active infection
* Onability or refusal to provide written informed consent
* enrollment in another clinical trial.
* Liver cirrhosis
* Current treatment for an active malignancy or active infection
* Onability or refusal to provide written informed consent
* enrollment in another clinical trial.
Minimum Eligible Age
60 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ministry of Health & Welfare, Korea
OTHER_GOV
Sponsor Role
collaborator
Soonchunhyang University Hospital
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Soon Hyo Kwon, MD
Professor
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Soon Hyo Kwon, MD
Role: PRINCIPAL_INVESTIGATOR
Soonchunhyang University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Soonchunhyang University Hospital Bucheon
Bucheon-si, , South Korea
Site Status
RECRUITING
Hallym University Medical Center- Chuncheon
Chuncheon, , South Korea
Site Status
COMPLETED
Soonchunhyang University Seoul Hospital
Seoul, , South Korea
Site Status
ACTIVE_NOT_RECRUITING
Kangbuk Samsung Medical Center
Seoul, , South Korea
Site Status
COMPLETED
Koera University Guro Hospital
Seoul, , South Korea
Site Status
COMPLETED
The Catholic University of Korea, Yeouido St. Mary's Hospital
Seoul, , South Korea
Site Status
COMPLETED
Yonsei University, Wonju Severance Christian Hospital
Wŏnju, , South Korea
Site Status
COMPLETED
Countries
Review the countries where the study has at least one active or historical site.
South Korea
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Byung Chul Yu, MD
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Han M, Jeon H, Yu BC, Song SH, Chung S, Lim C, Sohn H, Noh JW, Kwon SH; PRIDE Research Group. A Pragmatic Randomized clinical trial: twice-weekly vs. thrice-weekly Incident hemoDialysis in Elderly patients (PRIDE): study protocol. Kidney Res Clin Pract. 2023 Dec 18. doi: 10.23876/j.krcp.23.177. Online ahead of print.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HC21C0059
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Quality of Life of Frail Aged Patients in Incremental Hemodialysis
NCT03782519
UNKNOWN
NA
Effects of On-Line Hemodiafiltration(HDF) on Vascular Health in Chronic Hemodialysis Patients
NCT00532597
UNKNOWN
PHASE4
Impact of Dialysis Modality on Coagulation and Platelet Function
NCT04512131
COMPLETED
Cognitive and Functional Status and Dialysis Outcomes in Older Hemodialysis Patients
NCT00739843
TERMINATED
Dialysis-Less Frequently In The Elderly
NCT03787719
COMPLETED
NA
The Protective Effect of Remote Ischemic Conditioning on Residual Renal Function in Hemodialysis Patients (RIC-HD)
NCT06275152
ENROLLING_BY_INVITATION
NA
Effects of Extended Haemodialysis Treatment Duration in Patients With End-stage Renal Disease
NCT01721421
UNKNOWN
NA
Comparison of Four and Eight Hours Dialysis Sessions in Thrice Weekly Hemodialysis
NCT00413803
COMPLETED
PHASE4
Change From Baseline to Chronic Kidney Disease Patient Before and After Administration Drug
NCT02378194
COMPLETED
PHASE2
More Frequent Dialysis (>3 Treatments Per Week)
NCT00575497
COMPLETED
NA
Comparison of Outcomes Between Hemodialysis and Peritoneal Dialysis Patients in a Multi-Ethnic Asian Population
NCT01587443
UNKNOWN
In-Centre Nocturnal Hemodialysis (INHD): A Long-Term Follow-Up Study
NCT02684773
COMPLETED
Individualized Incremental Hemodialysis Study
NCT03352271
COMPLETED
NA
Evaluation of a Pathway on the Evolution of Renal Function in Patients With Advanced Chronic Kidney Disease
NCT06219798
RECRUITING
The Hemodynamic Effects During Sustained Low-efficiency Dialysis Versus Continuous Veno-venous Hemofiltration for Patients With Intracranial Hypertension in a Cross Over Study
NCT01781585
WITHDRAWN
Hemodialysis in the Elderly (70yrs & Older)
NCT03065972
UNKNOWN
NA
Comparison of Daily Home Hemodialysis (HD) With Conventional in Center HD in Terms of Patients Quality of Life and Clinical Outcomes
NCT03737578
UNKNOWN
NA
Comparison of Standard Versus High Dose Urokinase for Dysfunctional Tunneled Dialysis Catheters in Haemodialysis Patients: a Randomized Controlled Trial
NCT06802679
COMPLETED
PHASE4
High Versus Standard Volume Hemodiafiltration in Asia
NCT02092194
UNKNOWN
NA
Three Anticoagulation Strategies for Hemodialysis in Patients at Risk of Hemorrhage
NCT03419923
UNKNOWN
NA
Impact of Regular Low-Frequency Hemoperfusion on Medium- to Long-Term Prognosis in Maintenance Dialysis Patients
NCT07348913
COMPLETED
High Flux Hemodialysis Thrice Versus Once
NCT00714662
UNKNOWN
PHASE3
Incremental Hemodialysis for Veterans in the First Year of Dialysis (IncHVets)
NCT05465044
RECRUITING
NA
Long-term, High Blood Flow Hemoadsorption Therapy in Patients Undergoing Maintenance Hemodialysis
NCT06574425
ENROLLING_BY_INVITATION
PHASE4